This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claims 1-8 (previously cancelled)

Claim 9 (Cancelled)

- 10. (previously amended) A liposome composition which comprises
 - (i) an antineoplastic alkylphospholipid,
- (ii) an antineoplastic water -or lipid-soluble antiestrogen associated in liposomal form with said antineoplastic alkylphospholipid,
 - (iii) a nonneoplastic phospholipid, and

optionally one or more of (iv) a sterol, (v) a positively or negatively charged lipid, and (vi) a PEG lipid.

11. (previously amended) The composition of claim 10, wherein said alkylphospholipid has the formula

R-Y-P-X

wherein

R is a C₁₂₋₂₂ alkyl, alkenyl, or alkinyl residue,

Y is oxygen, sulfur, or a CH₂ residue,

P is a PO2 residue, and

X is a choline, or modified choline residue, or serine, ethanolamine, or glycerine group, or a synthetic modification thereof.

- 12. (previously amended) The composition of claim 10, wherein said alkylphospholipid is hexadecylphosphoicholine, octadecylphosphocholine, erucylphosphocholine, octadecyl-[2-(N-methylpiperidino)ethyl]phosphate, octadecylphosphochanolamine, or hexadecyl-phosphoserine.
- 13. (previously amended) The composition of claim 10, wherein said antiestrogen is tamoxifen, droloxifen, toremifen, idoxiphen, raloxiphen, miproxiphen-phosphate (TAT-59), 7α -[9-[N-butyl-N-methylaminocarbonyl]decyl]estra-1,3,5(10)-triene-3,17 β -diol, 7α -[9-[4,4,5,5,5-pentafluoropentyl)sulfonyl]estra-1,3,5(10)-triene-3,17 β -diol, 4-hydroxy tamoxi- phen, N-desmethyltamoxiphen.

- 14. (previously amended) The composition of claim 10, wherein said nonneoplastic phospholipid is a naturally occurring or synthetic material, with a lipid: antiestrogen molar ratio of between 0-10: 1 (m/m).
- 15. (previously amended) The composition of claim 14, wherein said nonneoplastic phospholipid is phosphocholine, serine, ethanolamine, glycerol.
- 16. (previously amended) The composition of claim 10, wherein said sterol is cholesterol, or sitosterol in a sterol: alkylphospholipid molar ratio of 0-1:1.
- 17. (previously amended) The composition of claim 10, wherein said PEG lipid is N-(O-methoxy-polyethyleneglycyl)-1,2-distearyl-s,n-glycero-3-phosphoethanolamine (PEG₂₀₀₀-DSPE).
- 18. (previously amended) The composition of claim 10, wherein said antineoplastic phospholipid is octadecyl-(N,N-diemthylpiperidin-4-yl)-phosphate, and said antineoplastic antiestrogen is tamoxiphen.